argenex, Dianthus Therapeutics, and Danaher are the three Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of companies that develop products and technologies based on biology, such as drugs, vaccines, gene therapies, and diagnostic tools. For stock market investors, they are often considered high-risk, high-reward investments because their value can change sharply based on clinical trial results, regulatory approvals, and scientific breakthroughs. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
argenex (ARGX)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Dianthus Therapeutics (DNTH)
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Read Our Latest Research Report on DNTH
Danaher (DHR)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Read Our Latest Research Report on DHR
Featured Stories
- MarketBeat’s Top Five Stocks to Own in June 2026
- Nebius Group’s £1.7 Billion UK Expansion Fuels Bullish Case Despite the Pullback
- An Analyst Just Raised Tesla’s Price Target by 227%—Here’s Why
- AST SpaceMobile’s SpaceX Catalyst Could Come With a Volatility Warning
- GameStop’s $2 Billion Buyback Sends a Confusing Signal to Investors
- FuelCell Energy Just Got a Wake-Up Call From Wall Street
